Donald A. Deieso, PhD

Executive Chairman & Chief Executive Officer (CEO)


Dr. Deieso became executive chairman of WCG in 2012. He assumed the additional role of CEO in October 2013. Since 2011, Dr. Deieso has also served as an operating partner and co-head of the Healthcare Group at Arsenal Capital Partners.

Before assuming these positions, Dr. Deieso served as CEO of a number of publicly-traded and privately-held companies in the healthcare, life science, technology and engineering industries. Additionally, he held senior positions in federal and state regulatory agencies.

Dr. Deieso has led successful transformations of a number of companies in the healthcare and life science sectors gaining the recognition of leading a Deloitte Fast 500 Company for three consecutive years and being named an Ernst & Young Entrepreneur of the Year Finalist in 2010. He was named one of the 20 Innovators Changing the Face of the Clinical Trials Industry by CenterWatch in 2013 and was honored as a member of the PharmaVOICE 100 Most Inspiring Life Science Leaders in 2016 and again in 2019.

Underscoring his commitment to the healthcare industry, Dr. Deieso serves as a member of the board of directors for BioIVT, TractManager, and Inspire. Previously, he also served on the board of directors for Certara, Breckenridge Financial Services, and IMDS. In addition, he is a former member of the board of trustees for the Kenan Institute of the University of North Carolina and the NJ Symphony Orchestra.

Dr. Deieso received a BS in mechanical engineering from Manhattan College, and an MS and PhD from Rutgers University, where he served on the faculty. He lectures and writes frequently on compliance matters related to clinical research and compliance within the life science industry.